Cited 17 times in
Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 원희관 | - |
dc.contributor.author | 이병완 | - |
dc.contributor.author | 이현철 | - |
dc.contributor.author | 차봉수 | - |
dc.contributor.author | 강은석 | - |
dc.contributor.author | 김광준 | - |
dc.date.accessioned | 2014-12-19T16:45:03Z | - |
dc.date.available | 2014-12-19T16:45:03Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0742-3071 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90123 | - |
dc.description.abstract | AIM: To investigate whether the change in glycated albumin 3 weeks after initiating anti-diabetes treatment (oral hypoglycaemic agent or insulin) could predict the corresponding change in HbA(1c) 3 months later in Korean patients with Type 2 diabetes. METHODS: A total of 140 patients were enrolled into two groups: group I (insulin-based; n = 100) and group II (oral hypoglycaemic agent-based; n = 40). Both glycated albumin and HbA(1c) levels were measured as 'glucose control markers' during hospitalization. Glycated albumin was measured again at 3 weeks (first visit) after the initial measurement, and HbA(1c) was measured at 3 months (second visit) after the initial measurement.. The change in glucose control marker was defined as 100 × (follow-up glucose control marker--hospital glucose control marker)/hospital glucose control marker. RESULTS: In both groups, the change in glycated albumin at the first visit and in HbA(1c) at the second visit showed a moderate linear relationship (r = 0.735; P < 0.01). In group II (r = 0.778; P < 0.01), a slightly stronger linear relationship was demonstrated than in group I (r = 0.738; P < 0.001); however, there was no statistically significant difference between the two groups. A correlation coefficient between the change in glycated albumin and HbA(1c) was not affected by sex, age, BMI, haemoglobin, serum creatinine or albumin. CONCLUSION: The reduction in glycated albumin 3 weeks after the initiation of treatment corresponded with the reduction in HbA(1c) 3 months after starting treatment in both the group treated with a oral hypoglycaemic agent and the insulin-treated group of Korean patients with Type 2 diabetes. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | DIABETIC MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Analysis of Variance | - |
dc.subject.MESH | Blood Glucose/drug effects* | - |
dc.subject.MESH | Blood Glucose/metabolism | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/blood | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/drug therapy* | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/epidemiology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Glycated Hemoglobin A/drug effects* | - |
dc.subject.MESH | Glycated Hemoglobin A/metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents/administration & dosage* | - |
dc.subject.MESH | Insulin/administration & dosage* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Serum Albumin/drug effects* | - |
dc.subject.MESH | Serum Albumin/metabolism | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | H. K. Won | - |
dc.contributor.googleauthor | K. J. Kim | - |
dc.contributor.googleauthor | B.-W. Lee | - |
dc.contributor.googleauthor | E. S. Kang | - |
dc.contributor.googleauthor | B. S. Cha | - |
dc.contributor.googleauthor | H. C. Lee | - |
dc.identifier.doi | 10.1111/j.1464-5491.2011.03386.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02449 | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A03301 | - |
dc.contributor.localId | A03996 | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A00317 | - |
dc.relation.journalcode | J00726 | - |
dc.identifier.eissn | 1464-5491 | - |
dc.identifier.pmid | 21781151 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2011.03386.x/abstract | - |
dc.subject.keyword | glycated albumin | - |
dc.subject.keyword | HbA1c | - |
dc.subject.keyword | insulin | - |
dc.subject.keyword | oral hypoglycaemic agent | - |
dc.subject.keyword | Type 2 diabetes | - |
dc.contributor.alternativeName | Won, Hee Kwan | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.alternativeName | Lee, Hyun Chul | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | Won, Hee Kwan | - |
dc.contributor.affiliatedAuthor | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | Lee, Hyun Chul | - |
dc.contributor.affiliatedAuthor | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | Kim, Kwang Joon | - |
dc.citation.volume | 29 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 74 | - |
dc.citation.endPage | 79 | - |
dc.identifier.bibliographicCitation | DIABETIC MEDICINE, Vol.29(1) : 74-79, 2012 | - |
dc.identifier.rimsid | 32374 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.